Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Small cap

Panacea Biotec's auditor flags going concern as losses widen

Audited results for FY26 show a standalone net loss of ₹2,988 lakh, more than double the prior year, with the auditor questioning the company's ability to continue.


Mkt cap₹2,529 cr
ROE0.00%
Debt / eq.0.03
₹2,988 lakh FY26 standalone net loss, up from ₹1,523 lakh in FY25.

What's new

  • Auditor issued a going-concern qualification, citing negative retained earnings.
  • FY26 standalone net loss ballooned to ₹2,988 lakh from ₹1,523 lakh in FY25.
  • Board skipped the dividend and appointed a new independent director.

Why this matters

A going-concern flag is the auditor's blunt assessment that the company's viability is in question. Paired with a loss that more than doubled, it moves Panacea from a cyclical slump into a structural survival test.

What we're watching

  • Management's plan to address the negative retained earnings and auditor's concern.
  • Any concrete steps to restructure debt or secure new funding.
  • The new independent director's mandate and any board-level strategy shifts.

The full read

Panacea Biotec's auditor has dropped a going-concern qualification into the FY26 audit report, citing negative retained earnings. This is the sharpest signal in accounting: the person who signed off on the books doesn't see a clear path forward. The financials back that up. Standalone net loss more than doubled to ₹2,988 lakh from ₹1,523 lakh in FY25. The board skipped the dividend and added a new independent director, but those are sidebars. The core issue is the auditor's formal doubt, which changes how lenders, suppliers, and partners assess counterparty risk. The loss trajectory alone would warrant attention. The qualification turns it into a governance and solvency question.

Questions answered

What did the auditor actually say about the company's future?
The auditor issued a going-concern qualification in the FY26 audit report. This means, based on the financial statements, the auditor has material doubt about Panacea Biotec's ability to continue operating.
How much did the losses grow?
The standalone net loss for FY26 was ₹2,988 lakh, more than the ₹1,523 lakh loss recorded in FY25.
Why was the dividend skipped?
The board did not declare a dividend due to the company's continued losses. This is standard practice when a company is unprofitable.
What else did the board do in this meeting?
Besides approving the audited results and skipping the dividend, the board appointed a new independent director.
Mentioned: Going-concern qualification · ₹2,988 lakh FY26 loss · New independent director
Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.